Effect of chemically modified tetracycline on transforming growth factor-β1 and caspase-3 activation in liver of septic rats

Critical Care Medicine

Volumn 33, Issue 7, 2005, Pages 1577-1581

  Maitra, Subir R ^a   Shapiro, Marc J ^a   Bhaduri, Sikha ^a   El Maghrabi, M Raafat ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cecal ligation and puncture; Matrixmetalloproteinase 2; Matrixmetalloproteinase 9; Rat; Signaling; Tissue inhibitor of metalloproteinase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 8; CHEMICALLY MODIFIED TETRACYCLINE 3; FIBRONECTIN; GELATINASE; GELATINASE A; GELATINASE B; PROCASPASE 3; PROCASPASE 8; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CATALYSIS; CECUM; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; IMMUNOBLOTTING; LIVER; LIVER PARENCHYMA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SEPSIS; SIGNAL TRANSDUCTION;

EID: 22144470856     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000169880.82060.F7     Document Type: Article

References (25)

1. Woessher JF: The family of metalloproteinases. Ann NY Acad Sci 1994; 732:11-21
2. Kahari VM, Saviaclo KU: Matrix metalloproteinases and their inhibitions in tumor growth. Ann Med 1999; 31:34-45
3. Maitra SR, Bhaduri S, Valane P, et al: Inhibition of matrix metalloproteinase by chemically modified tetracyclines in sepsis. Shock 2003; 20:280-285
4. Maitra SR, Bhaduri S, Chen E, et al: Role of chemically modified tetracycline on TNF-α and mitogen activated protein kinase in sepsis. Shock 2004; 22:478-481
5. Cain K, Freathy C: Liver toxicity and apoptosis: Role of TG-β1, cytochrome c and the apoptosome. Toxicol Lett 2001; 120:307-315
6. Laun RA, Schroder O, Schoppnies M, et al: Transforming growth factor β1 and major trauma: Time dependent association with hepatic and renal insufficiency. Shock 2003; 19:16-23
7. Yu Q, Stamenkovic I: Cell surface localized matrix metalloproteinase-9 proteolytically activates TGFβ1 and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14:163-176
8. Leu JD, Crissey M, Taub R: Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1 deficient mice. J Clin Invest 2003; 111:129-139
9. Golub LM, Lee HM, Ryan ME, et al: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12:12-26
10. Trachtman H, Futterweit S, Greenwald R, et al: Chemically modified tetracyclines inhibit inducible nitric oxide production in cultured rat mesangial cells. Biochem Biophys Res Commun 1996; 229:243-248
11. Mitscher LA: The Chemistries of Tetracyclines. New York, Marcel Dekker, 1978, pp 172-180
12. Greenwald RA, Golub LM, Ramamurthy NS, et al: In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation. Bone 1998; 22:33-38
13. Seftor RE, Seftor EA, De Larco JE, et al: Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998; 16:217-225
14. Brown PD: Matrix metalloproteinases inhibitors in the treatment of cancer. Med Oncol 1997; 14:1-10
15. Lowry OH, Rosbrough NJ, Farr AL, et al: Protein measurement with the folinphenol reagent. J Biol Chem 1951; 193:265-275
16. Fairbanks G, Steck TL, Wallach DF: Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochem 1971; 10:2606-2617
17. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685
18. Steinberg J, Halter J, Schiller HJ, et al: Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 2003; 111:185-195
19. Nakamum T, Ebiham I, Skimada N, et al: Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock. Effect of fiber-immobilized polymyxin β treatment. Am J Med Sci 1998; 316:355-360
20. Lalu M, Gao C, Schultz R: Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. Mol Cell Biochem 2003; 251:61-66
21. Winwood PJ, Schuppan D, Iredale JP, et al: Kupffer cell derived 95-kd type iv collagenase/gelatinase b: Characterization and expression in cultured cells. Hepatology 1995; 22:304-315
22. Fingleton B: CMT-3 CollaGenex. Curr Opin Investig Drugs 2003; 4:1460-1467
23. Colletti LM, Kunkel SL, Walz A, et al: The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 1996; 23: 506-514
24. Deitch EA: Gut-liver axis in multiple system organ failure: Role of bacterial translocation and endotoxemia. In: Multiple Systems Organ Failure: Hepatic Regulation of Systemic Host Defense. Matuschak GM (Ed). New York, Marcel Dekker, 1993, p 39
25. Wang P, Ba ZF, Chaudry IH: Hepatocellular dysfunction occurs earlier than the onset of hyperdynamic circulation during sepsis. Shock 1995; 3:21-26